Business Context and Reporting Period
Company: OrthoPediatrics Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: December 7, 2018
Event: Entry into a Material Definitive Agreement for an underwritten public offering of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than operational performance metrics. Specific figures include:
- Shares Offered: 1,500,000 shares of Common Stock.
- Public Offering Price: $27.00 per share.
- Underwriting Price: $25.38 per share.
- Over-Allotment Option: 30-day option to purchase up to 225,000 additional shares.
- Expected Net Proceeds: Approximately $37.7 million (after underwriting discounts and estimated offering expenses).
Note: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures. These metrics are not the subject of this specific 8-K report.
Material Changes
The primary material change is the execution of an Underwriting Agreement with Piper Jaffray & Co. and Stifel, Nicolaus & Company, Incorporated. This agreement facilitates the sale of equity to raise capital, representing a significant change in the company's capital structure pending the closing of the offering.
Guidance, Outlook, and Risks
- Closing Date: Expected on or about December 11, 2018, subject to customary closing conditions.
- Forward-Looking Statements: The filing includes a cautionary note regarding statements about the timing and completion of the Offering and the amount of net proceeds. Actual results may differ materially due to risks detailed in the Company's Form 10-K and the preliminary prospectus supplement.
- Legal Framework: The offering is conducted pursuant to a shelf registration statement on Form S-3 declared effective on November 9, 2018.
Investor Verification Checklist
- Verify the final closing date of the Offering (expected December 11, 2018).
- Confirm whether the underwriters exercised the 30-day option to purchase the additional 225,000 shares.
- Review the final net proceeds received after all offering expenses are deducted.
- Examine the full text of the Underwriting Agreement (Exhibit 1.1) for specific covenants and termination provisions.
- Check subsequent filings for the impact of the new capital on the company's liquidity and balance sheet.